LQDA — Liquidia Corporation stock price, charts and financials

QT77Liquidia Corporation

Liquidia Corporation (NASDAQ: LQDA) is a Healthcare company in the Medical - Pharmaceuticals industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
66.88
-1.51-2.21%
OverviewShort InterestFilings
LQDAQT77Liquidia Corporation·NASDAQ
66.88-2.21%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
KNSA-2.63%$77.24CORT-3.98%$110.29PBH-3.23%$44.97RPRX-0.88%$58.41PTGX-0.49%$143.00BRKR-2.63%$61.39ARWR-1.86%$66.48MASI+0.00%$179.95
Snapshot
Index-P/E48.82EPS (ttm)1.37Insider Own17.61%Shs Outstand88.93MPerf Week0.21%
Market Cap5.95BForward P/E12.01EPS next Y5.57Insider Trans-20.90%Shs Float62.33MPerf Month-11.22%
Enterprise Value5.79BPEG1.67EPS next Q0.90Inst Own-Short Float19.02%Perf Quarter-5.90%
Income139.00MP/S13.19EPS this Y123.94%Inst Trans-Short Ratio6.24Perf Half Y79.01%
Sales451.00MP/B30.50EPS next Y81.47%ROA26.56%Short Interest11.86MPerf YTD93.91%
Book/sh2.19P/C20.94EPS next 5Y29.19%ROE149.64%52W High93.60 -28.55%Perf Year167.52%
Cash/sh3.19P/FCF98.08EPS past 3/5Y-ROIC46.86%52W Low21.15 216.22%Perf 3Y862.30%
Dividend Est.-EV/EBITDA32.54Sales past 3/5Y114.54% 175.25%Gross Margin92.48%Volatility4.47% 4.06%Perf 5Y2358.82%
Dividend TTM-EV/Sales12.84EPS Y/Y TTM182.53%Oper. Margin37.39%ATR (14)3.35Perf 10Y-
Dividend Ex-Date-Quick Ratio2.12Sales Y/Y TTM3121.43%Profit Margin30.74%RSI (14)40.97Recom2.14
Dividend Gr. 3/5Y-Current Ratio2.31EPS Q/Q251.02%SMA20-2.12%Beta0.54Target Price98.11
Payout0.00%Debt/Eq4.38Sales Q/Q1811.11%SMA50-12.42%Rel Volume2.54Prev Close68.39
Employees216LT Debt/Eq3.09EarningsNov 02SMA20026.17%Avg Volume1.53MPrice66.88
IPO DateJul 26, 2018Option/ShortYes / YesEPS/Sales Surpr.-2.34% 1.90%Net Debt/EBITDA-0.87Volume3,895,583Change-2.21%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-13-26ReiteratedRaymond JamesStrong Buy$68 → $106
Aug-13-26ReiteratedWells Fargo$62 → $108
Jul-24-26ReiteratedStephens$130
Jul-24-26ReiteratedH.C. WainwrightBuy$130 → $36
Jul-24-26ReiteratedPiper Sandler$129
Jul-24-26ReiteratedRBC Capital$130
Jul-23-26ReiteratedH.C. WainwrightBuy$75 → $130
Jun-22-26ReiteratedBTIGBuy$59 → $109
Jun-05-26ReiteratedH.C. WainwrightBuy$67 → $75
Jun-05-26ReiteratedOppenheimer$13 → $75
Latest News· Times ET
Sep-14-26
Sep-14-2611:26PM
California State Teachers Retirement System Acquires 5,835,156 Shares of Liquidia Corporation $LQDAdefenseworld.net
Sep-11-26
Sep-11-2611:26AM
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?zacks.com
Sep-10-26
Sep-10-2610:40AM
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?zacks.com
Sep-04-26
Sep-04-2611:08PM
Does FDA Fast Track For YUTREPIA In SSc Raynaud’s Change The Bull Case For Liquidia (LQDA)?Yahoo
Sep-03-26
Sep-03-2603:30AM
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosisglobenewswire.com
Sep-02-26
Sep-02-2604:30AM
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congressglobenewswire.com
Sep-01-26
Sep-01-2604:30AM
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conferenceglobenewswire.com
Aug-31-26
Aug-31-2607:16AM
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?zacks.com
06:31AM
Is the Options Market Predicting a Spike in Liquidia Stock?zacks.com
Aug-28-26
Aug-28-2603:04PM
Liquidia Corp (LQDA) Stock Down 3.1% -- Now Undervalued? GF Score: 70/100gurufocus.com
07:58AM
Liquidia: A Linear Launch Priced For Exponential Growthseekingalpha.com
Aug-27-26
Aug-27-2611:26AM
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?zacks.com
Aug-24-26
Aug-24-2611:46AM
Will LQDA's Differentiated PAH Approach Drive Growth?zacks.com
Aug-20-26
Aug-20-2602:47PM
Liquidia Corp (LQDA) Shares Fall 5.8% -- What GF Score of 70 Tells Investorsgurufocus.com
Aug-19-26
Aug-19-2611:41AM
Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?zacks.com
Company

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue45115814——————
Cost of Goods Sold Incl. D&A34136——————
Gross Profit4171458——————
Selling, General and Administrative Excl. Other19215782——————
Research and Development553948——————
Other Operating Expense10-1——————
Operating Income170-51-121——————
Interest Expense262412——————
Unusual Expense
—————————
Non-Operating Income (Expense)873——————
Net Income Before Taxes150-69-130——————
Income Taxes
1100——————
Consolidated Net Income139-69-130——————
Net Income From Continuing Operations139-69-130——————
Net Income139-69-130——————
EPS (Recurring)1.57-0.80-1.66——————
EPS (Basic, Before Extraordinaries)1.57-0.80-1.66——————
EPS (Diluted)1.37-0.80-1.66——————
EBITDA178-43-116——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
48.82————————
Price To Sales Ratio13.2018.7766.36——————
Gross Margin92.4691.7757.14——————
Operating Margin37.69-32.28-864.29——————
Net Margin30.82-43.67-928.57——————
Shares Outstanding898679——————
Market Capitalization5,9522,966929——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$102.57$77.57$52.56$27.55$2.55● Close Price0.00M20.70M41.40M62.10M82.80MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
SINGH RAMANDirectorSep 14 '26Sale66.168,468560,24344,637Sep 15
SINGH RAMANDirectorSep 14 '26Option Exercise9.318,46878,79953,105Sep 15
SINGH RAMANDirectorSep 11 '26Option Exercise9.269,02483,59753,661Sep 15
SINGH RAMANDirectorSep 11 '26Sale68.629,024619,21044,637Sep 15
Krepp SarahChief Human Resource OfficerSep 01 '26Sale67.7627418,566117,308Sep 03
Adair JasonChief Business OfficerAug 21 '26Sale69.0973,6315,087,224174,606Aug 25
Adair JasonChief Business OfficerAug 21 '26Option Exercise11.0031,799349,839248,237Aug 25
Rielly-Gauvin KatherineDirectorAug 20 '26Option Exercise2.5418,39346,70063,030Aug 21
Rielly-Gauvin KatherineDirectorAug 20 '26Sale72.2318,3931,328,47744,637Aug 21
Rielly-Gauvin KatherineDirectorAug 19 '26Option Exercise2.5436,78993,40781,426Aug 21
Rielly-Gauvin KatherineDirectorAug 19 '26Sale74.9936,7892,758,95844,637Aug 21
Saggar RajeevChief Medical OfficerAug 19 '26Option Exercise3.7350,000186,500192,265Aug 19
Saggar RajeevChief Medical OfficerAug 19 '26Sale74.0650,0003,702,825142,265Aug 19
Saggar RajeevChief Medical OfficerAug 17 '26Sale76.8429,5342,269,381142,265Aug 19
Boyle DanaChief Accounting OfficerJul 27 '26Sale87.531,600140,048167,919Jul 29
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.